MedTrace Logo

AO-176 in Multiple Solid Tumor Malignancies

NCT03834948 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2023-08-22

No results posted yet for this study

Summary

This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.

Conditions

Interventions

DRUG

AO-176

Humanized monoclonal antibody (mAb) targeting CD47

DRUG

AO-176 + Paclitaxel

Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel

DRUG

AO-176 + Pembrolizumab

Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab

Sponsors & Collaborators

Principal Investigators

  • Benajmin Oshrine, MD · Arch Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2022-11-17
Completion
2023-02-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834948 on ClinicalTrials.gov